At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMNM Immunome Inc.
Pre-Mkt 12-23 05:59:43 EST
22.03
+0.59
+2.75%
High22.39Low21.23Vol2.51M
Open21.96D1 Closing21.44Amplitude5.41%
Mkt Cap2.43BTradable Cap2.07BTotal Shares110.34M
T/O54.92MT/O Rate2.68%Tradable Shares93.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Immunome CTO Philip Tsai Reports Acquisition of Common Shares
Reuters  ·  12-22 20:33
Immunome CTO Philip Tsai Reports Acquisition of Common Shares
Clay Siegall Bought 5.8% More Shares In Immunome
Simply Wall St.  ·  12-20 21:17
Clay Siegall Bought 5.8% More Shares In Immunome
Immunome CEO Clay B. Siegall Reports Acquisition of Common Shares
Reuters  ·  12-19
Immunome CEO Clay B. Siegall Reports Acquisition of Common Shares
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
Reuters  ·  12-17
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
Reuters  ·  12-17
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
BUZZ-Immunome slips after $400 mln stock sale
Reuters  ·  12-17
BUZZ-Immunome slips after $400 mln stock sale
Immunome Announces Pricing Of Public Offering Of 18,625,000 Shares At $21.50 Each
Reuters  ·  12-17
Immunome Announces Pricing Of Public Offering Of 18,625,000 Shares At $21.50 Each
Immunome Inc - Prices Public Offering of 18,625,000 Shares at $21.50 Each
THOMSON REUTERS  ·  12-17
Immunome Inc - Prices Public Offering of 18,625,000 Shares at $21.50 Each
ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn
Reuters  ·  12-17
ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
THOMSON REUTERS  ·  12-17
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Immunome Is Maintained at Buy by Guggenheim
Dow Jones  ·  12-16
Immunome Is Maintained at Buy by Guggenheim
Immunome Inc - Offering $400 Mln of Common Stock - SEC Filing
THOMSON REUTERS  ·  12-16
Immunome Inc - Offering $400 Mln of Common Stock - SEC Filing
BUZZ-Immunome dips after launching $400 mln stock offering
Reuters  ·  12-16
BUZZ-Immunome dips after launching $400 mln stock offering
Immunome Plans $400 Million Public Stock Offering
MT Newswires Live  ·  12-16
Immunome Plans $400 Million Public Stock Offering
Immunome Announces Proposed Public Offering of Common Stock
THOMSON REUTERS  ·  12-16
Immunome Announces Proposed Public Offering of Common Stock
Immunome Inc - to Commence $400 Mln Public Offering
THOMSON REUTERS  ·  12-16
Immunome Inc - to Commence $400 Mln Public Offering
BUZZ-U.S. STOCKS ON THE MOVE-Brystol Myers, Nvidia
Reuters  ·  12-16
BUZZ-U.S. STOCKS ON THE MOVE-Brystol Myers, Nvidia
Why Is Immunome Stock Soaring Monday?
Benzinga_recent_news  ·  12-16
Why Is Immunome Stock Soaring Monday?
Wedbush Adjusts Immunome Price Target to $31 From $21, Maintains Outperform Rating
MT Newswires Live  ·  12-15
Wedbush Adjusts Immunome Price Target to $31 From $21, Maintains Outperform Rating
Immunome Up Over 24%, on Pace for Record Percent Increase -- Data Talk
Dow Jones  ·  12-15
Immunome Up Over 24%, on Pace for Record Percent Increase -- Data Talk

Introduction

Company Name.
Immunome Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Issue price:
--